Equities

PURE Biosciences Inc

PURE:PKC

PURE Biosciences Inc

Actions
Basic MaterialsChemicals
  • Price (USD)0.16
  • Today's Change0.040 / 33.22%
  • Shares traded54.14k
  • 1 Year change+58.42%
  • Beta0.1768
Data delayed at least 15 minutes, as of Nov 13 2024 20:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products primarily in the food safety arena. The Company provides solutions to combat the health and environmental problems of pathogen and hygienic control. Its technology platform is based on patented, stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The Company offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. It also offers PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The Company sells its products directly and indirectly through third-party distributors.

  • Revenue in USD (TTM)1.96m
  • Net income in USD-3.35m
  • Incorporated2011
  • Employees11.00
  • Location
    PURE Biosciences Inc771 Jamacha Road #512EL CAJON 92019United StatesUSA
  • Phone+1 (619) 596-8600
  • Fax+1 (619) 596-8690
  • Websitehttps://www.purebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stephan Co13.73m-9.00m4.19m95.00--0.4617--0.3052-2.22-2.293.392.210.89932.8423.25144,505.30-58.92-8.68-65.81-9.4318.5436.69-65.52-12.062.56--0.0055---9.07-5.30-3,763.61--38.38-12.94
Megola Inc0.000.005.02m5.00--0.4034----0.000.000.000.04270.00------0.00-26.730.00-32.61-------200.57----0.00-------100.00------
Bemax Inc80.52k-199.53k5.13m--------63.67-205.09-205.091.18-1.160.5306-------131.49------2.67---247.80--0.2641-10.18-----72.37---16.44------
CCA Industries Inc8.23m-269.05k5.60m98.00--0.7409--0.6808-0.0356-0.03561.091.170.71221.4810.63---2.33-0.9542-2.98-1.2461.4859.95-3.27-0.91540.7109-0.57580.0681---18.32-8.78-682.80---41.70--
CleanCore Solutions Inc1.60m-2.28m17.33m7.00--4.64--10.80-0.3453-0.34530.23080.4540.23651.204.58229,281.40-33.62---56.20--49.58---142.17--1.69-5.810.4113---34.26--57.30------
PURE Biosciences Inc1.96m-3.35m17.90m11.00------9.12-0.03-0.030.0176-0.02561.4911.266.73178,454.50-253.50-71.64-486.21-93.7958.6955.75-170.66-79.321.02-20.2034.69--4.580.559515.43------
AXIL Brands Inc27.24m3.07m25.86m14.0017.193.2813.950.94920.23280.23282.081.222.452.8251.641,945,967.0015.6416.4222.0923.8972.3173.176.385.671.65--0.018--16.9194.3182.66--62.06--
Data as of Nov 13 2024. Currency figures normalised to PURE Biosciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.